

# Pacific Health Review

Making Education Easy

Issue 40 – 2025

## In this issue:

- Common mental health disorders among Pacific adults in NZ
- Cancer incidence among the NZ Pacific population
- Ethnic disparities in use of emergency medical services for ACS in NZ
- Disparities in patient mortality after ICU admission for sepsis in NZ
- Rheumatic fever trends in the Bay of Plenty
- Acute rheumatic fever in the Canterbury region
- Epidemiology of skin infections in the Auckland region
- Projected prevalence of diabetes in NZ
- Otago University's support of Pacific students during the COVID pandemic
- Modified APPEND score for diagnosis of acute appendicitis

### Abbreviations used in this issue

**COVID-19** = coronavirus disease 2019  
**ACS** = acute coronary syndrome  
**ICU** = intensive care unit  
**STEMI** = ST elevation myocardial infarction

### KINDLY SUPPORTED BY:



**Kia orana, Fakaalofa lahi atu, Talofa lava, Malo e lelei, Bula vinaka, Taloha ni, Kia ora, Greetings.**

## Welcome to the latest issue of Pacific Health Review.

This issue covers a range of topics of interest to Pacific people living in Aotearoa New Zealand and the Pacific Region, with a particular emphasis on health inequities.

We hope you find this issue interesting, and welcome your feedback.

Kind regards,

**Sir Collin Tukuitonga**

[collin.tukuitonga@pacifichealthreview.co.nz](mailto:collin.tukuitonga@pacifichealthreview.co.nz)

**Dr Roannie Ng Shiu**

[roannie.ngshiu@pacifichealthreview.co.nz](mailto:roannie.ngshiu@pacifichealthreview.co.nz)

## Common mental disorders and psychological distress among Pacific adults living in Aotearoa New Zealand

**Authors:** Ataera-Minster J et al.

**Summary:** This study examined the prevalence of common mental disorders (depression and anxiety) among Pacific adults living in NZ. Data were extracted from multiple NZ Health Survey waves from 2014/2015 to 2018/2019 for Pacific adults aged ≥15 years. Analysis of the data according to sociodemographic factors showed that doctor-diagnosed common mental disorders were more prevalent in Pacific women than in Pacific men, in adults aged 24–64 years versus 15–24 years, and in those living in the least deprived versus the most deprived areas. Depression and/or anxiety were more common in adults affiliated with Pacific Realm countries (Cook Islands Māori and Niueans) than in those affiliated with non-Realm countries. Psychological distress was found to be more prevalent in Pacific females and Cook Islands Māori.

**Comment:** This study presents interesting findings on depression and anxiety in Pacific adults living in NZ prior to COVID-19, albeit with methodological limitations (e.g. small population samples). The higher prevalence in people from Pacific Realm countries and those living in the least deprived areas points to the importance of providing targeted services for Pacific women, communities living in deprived areas and for adults from Pacific Realm countries. What is urgently needed is current data on the mental health of Pacific adults to provide longitudinal patterns of mental disorders across all Pacific communities to see whether these patterns remain, as well as to gain better insights into the levels of undiagnosed mental disorders across all Pacific populations. This information would be valuable for addressing growing gaps between mental health needs and services.

**Reference:** *N Z Med J.* 2025;138(1613):36–49

[Abstract](#)

To read previous issues of Pacific Health Review [CLICK HERE](#)



INDEPENDENT COMMENTARY BY

**Sir Collin Tukuitonga** KNZM

Sir Collin Tukuitonga is a medical graduate and Public Health Physician with extensive experience in health policy, research, management, and leadership in NZ and internationally. He is the inaugural Associate Dean Pacific and Associate Professor of Public Health at the University of Auckland. Prior to this role, he was the Director-General of the Pacific Community based in New Caledonia.



INDEPENDENT COMMENTARY BY

**Dr Roannie Ng Shiu**

Dr Roannie Ng Shiu is the Pasifika Medical Association (PMA) Senior Research Fellow with the University of Auckland Faculty and Medical and Health Sciences Office of the Associate-Dean Pacific. Her primary role is to deliver robust high-quality Pacific health equity research and to increase the Pacific health workforce in Aotearoa with the recruitment and retention of Pacific health students. She was previously with the Department of Pacific Affairs at the Australian National University. Roannie is Samoan and was raised in South Auckland and graduated from the University of Auckland with a PhD in Community Health.

Jardiance®  
(empagliflozin)

## JARDIANCE® PROTECTION<sup>1†</sup>



Not an actual patient.



ONE SIMPLE  
**10mg**  
DOSE <sup>Tablet not actual size.</sup> ≤ 10

To help protect patients with heart failure, independent of LVEF<sup>1-3\*\*</sup>

- to reduce the risk of hospitalisation for heart failure and CV death
- to slow kidney function decline

\*JARDIANCE is not funded for HF with LVEF >40%<sup>4</sup>

<sup>†</sup>JARDIANCE 10mg once daily, as an adjunct to standard of care therapy<sup>3</sup>

CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction. **References:** 1. JARDIANCE Data Sheet. 2. Packer M et al. N Engl J Med 2020;383:1413-24. 3. Anker SD et al. N Engl J Med 2021;385:1451-61. 4. Pharmac Schedule: <http://schedule.pharmac.govt.nz/ScheduleOnline.php>. Accessed March 2025.

**JARDIANCE® empagliflozin 10mg film coated tablets. Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>.**

**Indication:** JARDIANCE is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus: -to reduce the risk of CV death and hospitalisation for heart failure; -to slow kidney function decline. **Dosage and Administration:** Recommended dose is 10mg once daily. Can be taken with or without food. No dose adjustment is recommended based on age, renal function, or hepatic impairment. Type 2 diabetes mellitus (T2DM) patients with eGFR <30mL/min/1.73m<sup>2</sup>, recommended dose is limited to 10mg, consider additional glucose lowering treatment if required. **Contraindications:** Hypersensitivity to empagliflozin or any of the excipients. **Warnings and Precautions:** Patients with type 1 diabetes; ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); not recommended to initiate treatment in patients on dialysis; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); complicated urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **Interactions:** Diuretics; insulin and SU; interference with 15-anhydroglucitol assay; lithium. **Adverse Reactions:** **Very common:** hypoglycaemia (when used with metformin in combination with SU or insulin - patients with type 2 diabetes mellitus (T2DM)); volume depletion (patients with HF). **Common:** hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin - patients with T2DM); hypoglycaemia (patients with HF); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus (patients with T2DM); allergic skin reactions (e.g. rash, urticaria); increased urination (patients with T2DM); thirst (patients with T2DM); serum lipids increased; constipation. For other adverse reactions, see full Data Sheet. **Actions:** Empagliflozin is a reversible competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. Through inhibition of SGLT2, excessive glucose is excreted in the urine. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, downregulating sympathetic activity and reducing left ventricular wall stress as evidenced by lower NT-proBNP values and beneficial effects on cardiac remodeling, filling pressures and diastolic function. Other effects such as an increase in haematocrit, a reduction in body weight and blood pressure may further contribute to the beneficial effects observed independent of left ventricular ejection fraction. **PRESCRIPTION MEDICINE.** JARDIANCE is funded for the treatment of HF with reduced ejection fraction - Special Authority criteria apply. JARDIANCE is not funded for HF with documented left ventricular ejection fraction >40%. JARDIANCE® is a registered trademark of Boehringer Ingelheim. March 2025.



**Boehringer  
Ingelheim**

Boehringer Ingelheim (NZ) Ltd.  
PO Box 76216, Manukau City, Auckland 2241. Phone 0800 802 461.  
Copyright ©2025. PC-NZ-100529. TAPS MR11762. Prepared April 2025.

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.pacifichealthreview.co.nz](http://www.pacifichealthreview.co.nz)

## Capturing diversity in cancer incidence and outcomes among the New Zealand Pacific population using linked administrative data

**Authors:** Satherley N & Sporle A

**Summary:** This study investigated the incidence of cancer among Pacific people living in NZ. Analysis of data extracted from the NZ Cancer Registry for the period 1995–2022 showed that the incidence rate of all cancers in Pacific people was 201.7 per 100,000. There was variability in age-standardised all-cancer incidence among different Pacific groups, whereby the average annual incidence (per 100,000) was highest among Cook Islands Māori (217.5) and Tongans (217.7), and lowest among Tokelauan (192.4) and Fijian people (160.7). The overall incidence of gastric cancer among Pacific groups was 8.0 per 100,000. A higher rate was observed among those of Niuean and Samoan ethnicity, and lower rates were seen in Cook Islands Māori and Tokelauans. Mortality rates within 1–5 years after cancer diagnosis decreased over time.

**Comment:** This is an important methodological study investigating cancer incidences in Pacific populations. The findings demonstrate how administrative data can provide valuable insights, but for more robust analyses there is need for improved data collection and reporting methods for minority groups. The findings highlight key considerations for policymakers and health services when designing cancer prevention, screening and treatment programmes for a growing diverse Pacific population. Ongoing monitoring and research is needed to address data gaps arising from the high mobility of Pacific populations, particularly from NZ Realm countries.

**Reference:** *N Z Med J.* 2025;138(1613):50–66  
[Abstract](#)

DO YOU HAVE FAMILY AND FRIENDS  
WHO SHOULD BE RECEIVING  
**PACIFIC HEALTH  
REVIEW**

BUT THEY AREN'T HEALTH  
PROFESSIONALS?

Just send them to  
[www.pacifichealthreview.co.nz](http://www.pacifichealthreview.co.nz)  
and they can sign up to get the review  
sent directly to their inbox.



South  
**GPCME**  
General Practice Conference  
& Medical Exhibition



**14–17 AUGUST 2025**  
TE PAE CHRISTCHURCH  
CONVENTION CENTRE

[gpcme  
.co.nz](http://gpcme.co.nz)

## Variation in emergency medical service use for acute coronary syndromes by ethnicity: An Aotearoa New Zealand observational study

**Authors:** Dicker B et al.

**Summary:** This study investigated whether emergency medical service (EMS) use varies by ethnicity among patients with ACS in NZ. A total of 19,283 patients hospitalised with ACS in 2019–2021 were included. Overall, 25% of them had STEMI, 55% had non-STEMI, and 20% had unstable angina. In those with STEMI, EMS use was lower in Māori (adjusted odds ratio [aOR] 0.72, 95% CI 0.58–0.90), Pacific (aOR 0.64, 95% CI 0.48–0.87), Indian (aOR 0.63, 95% CI 0.43–0.86), and non-Indian Asian (aOR 0.52, 95% CI 0.37–0.74) patients compared with NZ Europeans. Findings were similar for non-STEMI. For patients with unstable angina, the odds of EMS use were lower for all ethnic groups compared with Europeans, but the reductions were not statistically significant (except for non-Indian Asian patients).

**Comment:** Pacific and Māori populations are disproportionately affected by cardiovascular disease compounded by a higher prevalence of risk factors such as diabetes, and are more likely to experience early onset of cardiovascular disease. Despite these factors highlighting the need for better prevention, intervention and treatment, this study reports ongoing and persistent health inequities for Pacific populations. The findings highlight the importance of access to EMS as well as increasing awareness of ACS symptoms for Pacific communities. These can help Pacific patients to access timely care and prevent deaths.

**Reference:** *N Z Med J.* 2025;138(1611):33–54

[Abstract](#)

## Disparities in patient mortality following intensive care admission due to adult community-acquired sepsis in Aotearoa New Zealand, 2009–2019

**Authors:** McTavish S et al.

**Summary:** This NZ study investigated disparities in patient mortality after ICU admission for community-acquired sepsis in 2009–2019. Patients were followed from ICU admission to time of death (or until 1 year post-hospital discharge). In-hospital mortality was 16.3%. Post-discharge mortality was 3.6% at 30 days, 9.1% at 180 days and 12.9% at 365 days. The risk of in-hospital mortality did not differ according to ethnicity or NZ Index of Deprivation quintile. However, significant differences in post-discharge mortality were observed for ethnicity, area deprivation quintile, and presence of severe comorbidities.

**Comment:** This is an important study in an area that is severely under researched. The findings underscore existing health disparities in mortality risk for Pacific and Māori populations and people living in areas of high deprivation that correlate with worse post-discharge outcomes. The findings suggest that factors external to hospital care play a critical role in patient recovery and survival. The presence of severe comorbidities and serious underlying health conditions common in Pacific patients were also identified as predictors of mortality following discharge. To improve outcomes for Pacific patients, enhanced post-discharge support is necessary to help mitigate mortality risks, as well as addressing social determinants of health such as transportation, healthcare literacy and timely access to health care. Future studies should focus on addressing barriers to post-discharge care and follow up and the role that community support networks can play in improving health outcomes and survival rates.

**Reference:** *N Z Med J.* 2025;138(1610):13–30

[Abstract](#)

**Join over 38,000  
Research Review subscribers**

and receive a regular copy by email.

Sign up at no cost [HERE](#)



## Rheumatic fever trends in the context of skin infection and Group A Streptococcal sore throat programmes in the Bay of Plenty: An observational study, 2000–2022

**Authors:** Malcolm J et al.

**Summary:** This study investigated whether hospital admissions for skin infections and acute rheumatic fever (ARF) in the Bay of Plenty declined for preschool, school-age and young adults after health initiatives addressing Group A Streptococcal (GAS) sore throats and skin infections commenced in 2011. Admissions for serious skin infections declined after 2011. Compared with rates in 2007–2010, skin infection admission rates for Māori in 2017–2019 declined by 40% in preschoolers, 14% in school-aged children and 24% in young adults. Rates of ARF in individuals aged <30 years declined by 29% from 2000–2010 to 2011–2019. Patients with ARF were predominantly Māori (90%), and 80% of cases were school-aged. Risk ratios were 24.33 for Māori versus NZ European; 3.97 for Māori with high versus moderate deprivation; and 2.23 for males versus females. Of 49 ARF cases in the Bay of Plenty in 2015–2022, 35 had recently had positive community or hospital GAS swabs.

**Comment:** Despite improvements in ARF interventions, this study shows that Pacific people and in particular preschoolers still exhibit high infection rates, indicating ongoing health challenges. To better understand these ongoing health challenges and provide solutions, future research should focus on understanding causal pathways linking social determinants to health outcomes in Pacific communities. Access to integrated models of care that combine health care and social support services for all Pacific communities can help address broader determinants of health. Research should also explore innovative approaches to engage Pacific children and young people.

**Reference:** *N Z Med J.* 2025;138(1609):15–44

[Abstract](#)

## Acute rheumatic fever in Canterbury, Aotearoa New Zealand, 2012–2022

**Authors:** Su'a T et al.

**Summary:** This study investigated the clinical characteristics of acute rheumatic fever (ARF) cases aged <30 years in the Canterbury region in 2012–2022. A total of 34 cases were identified. Twenty-nine cases were diagnosed with a first episode of ARF and five were diagnosed with rheumatic heart disease without a previously identified episode of ARF. Overall, ARF rates in Canterbury were significantly lower than those in the rest of NZ. The majority of patients receiving ongoing prophylactic treatment for ARF in the region had migrated from the North Island or the Pacific Region.

**Comment:** This is the first study of ARF in the South Island and it provides important baseline data about ARF in Canterbury. While Canterbury rates of ARF are significantly lower than the rest of Aotearoa, Pacific peoples were approximately 20 times more likely to be diagnosed with ARF than any other ethnic group. This underscores the need for targeted interventions for Pacific communities in Canterbury. Most patients receiving treatment in Canterbury were Pacific patients (69%) and were diagnosed in Auckland or the Pacific region. The migration finding highlights the importance of continuity of care across different health regions as well as the need for a robust national surveillance system.

**Reference:** *N Z Med J.* 2025;138(1609):45–55

[Abstract](#)



**Hauora  
Taiwhenua  
Rural Health  
Network**

CONNECT WITH RURAL ALLIED HEALTH PROFESSIONALS

**TOGETHER, STRONGER:  
JOIN US TO CHAMPION  
RURAL HEALTH**

- Advocate for Recruitment, Training & Education
- Receive Exclusive Event & Retail Discounts
- Unite & Contribute to Change
- Access Our Tikanga App
- Much More



WWW.HTRHN.ORG.NZ

## Epidemiology of skin infections in Auckland, New Zealand

**Authors:** Mala K et al.

**Summary:** This population-based study described the epidemiology of *Staphylococcus aureus* and *Streptococcal pyogenes* skin infections in the Auckland region. Skin swab cultures collected in primary care for over one-quarter of the Auckland population in 2010–2020 were analysed. *S. aureus* affected all demographics, whereas *S. pyogenes* infection rates were higher for children aged <10 years versus ≥10 years (rate ratio [RR] 3.1, 95% CI 3.1–3.2), for Māori and Pacific people versus European/Other (RR 4.7, 95% CI 4.6–4.8) and for individuals in the most socioeconomically deprived areas versus those in the least deprived areas (RR 2.1, 95% CI 1.9–2.3). *S. aureus* infection was found to be a risk factor for co-infection with *S. pyogenes*.

**Comment:** Skin infections are often considered minor. However, they can cause significant discomfort and, if untreated, can lead to long-term health problems, sepsis and death. In children, skin infections can also have profound impacts on learning and educational outcomes. Like many other health issues and diseases, skin infection rates are high for Pacific and Māori populations and for those living in high areas of deprivation. The high prevalence of skin infections including co-infection risk in Pacific children requires an urgent response to improve diagnosis, treatment and management of complications. Targeted public health interventions such as new treatments, vaccines and awareness to improve hygiene practices and early detection of skin infections (bacterial, viral and fungal) will help to reduce the health burden and health disparities.

**Reference:** *N Z Med J.* 2025;138(1609):56–69

[Abstract](#)

## Projected increases in the prevalence of diabetes mellitus in Aotearoa New Zealand, 2020–2044

**Authors:** Teng A et al.

**Summary:** This modelling study estimated the future combined prevalence of types 1 and 2 diabetes in NZ. National-level data on diabetes prevalence were extracted from the Virtual Diabetes Register to determine recent diabetes prevalence trends (2006–2019) and to project diabetes prevalence trends from 2020 to 2044. It was determined that the absolute volume of diabetes in NZ would increase by nearly 90% to more than 500,000 by 2044, and the age-standardised prevalence of diabetes would increase from around 3.9% of the population to 5.0% overall. The projected increase in prevalence of diabetes diagnoses was most marked in Pacific people, particularly females.

**Comment:** This study provides a compelling and sobering picture of projected diabetes prevalence in Aotearoa. Diabetes disproportionately affects Pacific peoples in Aotearoa, and this disparity is projected to worsen, widening the gap with European populations. The use of age-period-cohort modelling offers a more nuanced prediction by taking into account ageing and cohort effects. The findings are clear – urgent action is needed to address the broader root causes and risk factors of diabetes prevalence with targeted interventions for Pacific women and communities. While there has been an increase in research and interventions focused on addressing diabetes, more research is required to find effective and sustainable solutions to enhance preventative health measures and improve diabetes management that works for Pacific communities. These actions are needed to reduce the strain diabetes will have on the healthcare system and improve quality of life for thousands of people in Aotearoa.

**Reference:** *N Z Med J.* 2025;138(1608):94–106

[Abstract](#)

## Tertiary institution's duty of care for the health and well-being of Pacific students during COVID-19 pandemic

**Authors:** Sopoaga F et al.

**Summary:** This cross-sectional study explored the level of support provided by Otago University to Pacific tertiary students during the COVID-19 pandemic. An online survey was completed by 358 of 1277 (28%) Pacific students attending the university in 2022. Three-quarters of respondents reported having to isolate at some stage during the academic year, either because they had COVID-19 or were considered a close contact. 356 (99%) of them had received a health pack, and two-thirds (67.6%) had accessed other support from the University.

**Comment:** This study presents an important and useful snapshot into the experiences of Pacific tertiary students during COVID-19. While COVID-19 was an unprecedented global pandemic the responses provide important lessons to address future pandemics. Medical and health tertiary students are already under enormous stress with the demands of tertiary training and the added financial and health costs of the pandemic necessitated a strong pastoral care response from tertiary institutions. This research highlights the importance of strengthening support systems, addressing equity in health and education, and the benefits of collaborating with local communities to address the unique needs of ethnic minority groups.

**Reference:** *J Prim Health Care* 2025;17(1):17–22

[Abstract](#)

## Modified APPEND score for the diagnosis of acute appendicitis in a New Zealand Pasifika population

**Authors:** Pitesa R et al.

**Summary:** The APPEND score incorporates C-reactive protein (CRP) levels and was developed in NZ to assist with the diagnosis of acute appendicitis. This study evaluated a modified APPEND score without CRP (mAPPEND) for diagnosing appendicitis in a NZ Pacific population. One hundred and forty-three Pacific patients aged ≥5 years who presented to Middlemore Hospital with right iliac fossa pain in 2011 or 2017 were included; those with prior appendectomy or generalised peritonitis were excluded. Area under the receiver-operating characteristic curve (a measure of diagnostic performance) was comparable for both the APPEND and mAPPEND scores. The mAPPEND score had high diagnostic accuracy, with scores of 1 and 2 showing high sensitivity and negative predictive value; scores of 4 and 5 showing high specificity and positive predictive value, and a score of 3 being the most efficient.

**Comment:** This validation study provides insights into an important diagnostic development tool and shows the importance of validating clinical predictions across ethnic populations. While the sample size was small the findings point to promising advancements particularly for Pacific countries with limited resources – providing a simple and accurate diagnostic tool that does not require advanced imaging and biochemical testing. This will help with timely and accurate diagnostics and prevent costs associated with unnecessary procedures. Further large-scale validation research is needed to establish Pacific regional applicability and support implementation in clinical practice. Similar clinical validation studies would be of benefit for other diagnostic tools, especially those designed for non-communicable diseases.

**Reference:** *World J Surg.* 2025;49(4):868–72

[Abstract](#)

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

## Earn CPD Points

### GPs

Research Review publications, videos and e-Learning modules have been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and have been approved for up to **2 CME credits** per learning hour for Continuing Professional Development (CPD) purposes.

Please **CLICK HERE** to download RNZCGP Dashboard.

### Nurses

Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs.

For more information on how to claim CNE hours **CLICK HERE**.

